PMID- 36519023
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230616
IS  - 2218-6751 (Print)
IS  - 2226-4477 (Electronic)
IS  - 2218-6751 (Linking)
VI  - 11
IP  - 11
DP  - 2022 Nov
TI  - Immune profile analysis of peripheral blood and tumors of lung cancer patients 
      treated with immune checkpoint inhibitors.
PG  - 2192-2207
LID - 10.21037/tlcr-22-421 [doi]
AB  - BACKGROUND: Immune checkpoint inhibitors (ICIs) have become central to lung 
      cancer drug therapy, and establishing biomarkers that can predict effects and 
      adverse events (AEs) is awaited. We prospectively analyzed the association 
      between the immune-related molecular expression in peripheral blood mononuclear 
      cells (PBMCs) and lung cancer tissues, and the effects of ICI monotherapy. 
      METHODS: Twenty-one patients with advanced non-small cell lung cancer (NSCLC) who 
      received ICI monotherapy were included. Changes in the expression of 
      immune-related molecules in PBMCs before and after the administration of ICI were 
      analyzed by flow cytometry. The major histocompatibility complex (MHC) class I 
      and programmed cell death-ligand 1 (PD-L1) expression of cancer cells, and the 
      PD-L1, CD8 and CD103 expression of tumor infiltrating immune cells in lung cancer 
      tissue before the administration of ICI were confirmed by immunohistochemistry 
      (IHC). RESULTS: Twenty-one patients were investigated, including 11 
      adenocarcinoma and 10 squamous cell carcinoma cases. Anti-programmed cell death 
      protein-1 (PD-1) antibody (n=18) and anti-PD-L1 antibody (n=3) were administered. 
      The clinical responses were graded as follows: complete response (CR) (n=1), 
      partial response (PR) (n=7), stable disease (SD) (n=10) and progressive disease 
      (PD) (n=3). Among immune-related molecules expressed in PBMCs, the CD103(+) 
      CD39(+) CD8(+) T cell change after administration closely correlated with the 
      clinical response. In the univariate analyses of the factors associated with 
      progression-free survival (PFS), CD103(+) CD39(+) CD8(+) cell change after 
      administration was identified as a significant prognostic factor, while the 
      CD103(+) CD39(+) CD8(+) cell change after administration and Brinkman index were 
      independent prognostic factors in a multivariate analysis of the factors 
      associated with PFS. CONCLUSIONS: The CD103(+) CD39(+) CD8(+) cell change after 
      administration may predict the efficacy of ICIs.
CI  - 2022 Translational Lung Cancer Research. All rights reserved.
FAU - Ichiki, Yoshinobu
AU  - Ichiki Y
AD  - Department of General Thoracic Surgery, National Hospital Organization, Saitama 
      Hospital, Wako, Japan.
AD  - Second Department of Surgery, University of Occupational and Environmental 
      Health, School of Medicine, Kitakyushu, Japan.
FAU - Fukuyama, Takashi
AU  - Fukuyama T
AD  - Division of Biomedical Research, Kitasato University Medical Center, Kitamoto, 
      Japan.
FAU - Ueno, Mari
AU  - Ueno M
AD  - Department of Diagnostic Pathology, National Hospital Organization, Saitama 
      Hospital, Wako, Japan.
FAU - Kanasaki, Yoshiro
AU  - Kanasaki Y
AD  - Department of General Thoracic Surgery, National Hospital Organization, Saitama 
      Hospital, Wako, Japan.
FAU - Goto, Hidenori
AU  - Goto H
AD  - Department of General Thoracic Surgery, National Hospital Organization, Saitama 
      Hospital, Wako, Japan.
FAU - Takahashi, Mai
AU  - Takahashi M
AD  - Department of Respiratory Medicine, National Hospital Organization, Saitama 
      Hospital, Wako, Japan.
FAU - Mikami, Shuji
AU  - Mikami S
AD  - Department of Diagnostic Pathology, National Hospital Organization, Saitama 
      Hospital, Wako, Japan.
FAU - Kobayashi, Noritada
AU  - Kobayashi N
AD  - Division of Biomedical Research, Kitasato University Medical Center, Kitamoto, 
      Japan.
FAU - Nakanishi, Kozo
AU  - Nakanishi K
AD  - Department of General Thoracic Surgery, National Hospital Organization, Saitama 
      Hospital, Wako, Japan.
FAU - Hayashi, Shinichi
AU  - Hayashi S
AD  - Department of Respiratory Medicine, National Hospital Organization, Saitama 
      Hospital, Wako, Japan.
FAU - Ishida, Tsuyoshi
AU  - Ishida T
AD  - Department of Diagnostic Pathology, National Hospital Organization, Saitama 
      Hospital, Wako, Japan.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Transl Lung Cancer Res
JT  - Translational lung cancer research
JID - 101646875
CIN - Transl Lung Cancer Res. 2023 May 31;12(5):944-947. PMID: 37323171
PMC - PMC9742629
OTO - NOTNLM
OT  - CD103
OT  - Lung cancer
OT  - PD-1
OT  - immune checkpoint inhibitor (ICI)
OT  - tumor immunology
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at 
      https://tlcr.amegroups.com/article/view/10.21037/tlcr-22-421/coif). The authors 
      have no conflicts of interest to declare.
EDAT- 2022/12/16 06:00
MHDA- 2022/12/16 06:01
PMCR- 2022/11/01
CRDT- 2022/12/15 02:35
PHST- 2022/06/04 00:00 [received]
PHST- 2022/10/13 00:00 [accepted]
PHST- 2022/12/15 02:35 [entrez]
PHST- 2022/12/16 06:00 [pubmed]
PHST- 2022/12/16 06:01 [medline]
PHST- 2022/11/01 00:00 [pmc-release]
AID - tlcr-11-11-2192 [pii]
AID - 10.21037/tlcr-22-421 [doi]
PST - ppublish
SO  - Transl Lung Cancer Res. 2022 Nov;11(11):2192-2207. doi: 10.21037/tlcr-22-421.